The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus

European Journal of Internal Medicine

Volumn 19, Issue 2, 2008, Pages 115-121

  Alizadeh Dehnavi, Reza ^a   Beishuizen, Edith D ^a   van de Ree, Marcel A ^b   Le Cessie, Saskia ^a   Huisman, Menno V ^a   Kluft, Cornelis ^c   Princen, Hans M G ^c   Tamsma, Jouke T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

^c TNO   (Netherlands)

Author keywords

C reactive protein; Diabetes mellitus type 2; Endothelial function; Intima media thickness; Metabolic syndrome; PAI 1

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; E-SELECTIN; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TUNICA INTIMA; TUNICA MEDIA; VASCULAR CELL ADHESION MOLECULE-1; VON WILLEBRAND FACTOR;

EID: 38749101984     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.06.011     Document Type: Article

References (39)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 19 (1979) 2035-2038
2. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. American Diabetes Association Diabetes Care 12 8 (1989) 573-579
3. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. diabetes care 16 2 (1993) 434-444
4. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 5 (2003) 1210-1214
5. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 4 (1998) 229-234
6. Ridker P.M., Wilson P.W., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 23 (2004) 2818-2825
7. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 3 (2003) 391-397
8. Järvisalo M.J., Harmoinen A., Hakanen M., Paakkunainen U., Viikari J., Hartiala J., et al. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol 22 8 (2002) 1323-1328
9. Blackburn R., Giral P., Bruckert E., André J.M., Gonbert S., Bernard M., et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 21 12 (2001) 1962-1968
10. Heinrich J., Schulte H., Schonfeld R., Kohler E., and Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73 3 (1995) 374-379
11. Hak A.E., Stehouwer C.D., Bots M.L., Polderman K.H., Schalkwijk C.G., Westendorp I.C., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19 8 (1999) 1986-1991
12. Willeit J., Kiechl S., Oberhollenzer F., Rungger G., Egger G., Bonora E., et al. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 20 2 (2000) 529-537
13. Timpson N.J., Lawlor D.A., Harbord R.M., Gaunt T.R., Day I.N., Palmer L.J., et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366 9501 (2005) 1954-1959
14. Arad Y., Newstein D., Cadet F., Roth M., and Guerci A.D. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol 21 12 (2001) 2051-2058
15. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24 8 (2001) 1335-1341
16. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf Available at: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf. Accessed December 12, 2003
17. de Maat M.P., de Bart A.C., Hennis B.C., Meijer P., Havelaar A.C., Mulder P.G., et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 16 9 (1996) 1156-1162
18. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 17 4 (1957) 237-246
19. Meijer P., Pollet D.E., Wauters J., and Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem 40 1 (1994) 110-115
20. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 47 2 (1987) 143-149
21. van Venrooij F.V., van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., Banga J.D., et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25 7 (2002) 1211-1216
22. Naumnik B., Borawski J., Pawlak K., and Mysliwiec M. Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers. Nephrol Dial Transplant 17 3 (2002) 526-528
23. Rustom R., Leggat H., Tomura H.R., Hay C.R., and Bone J.M. Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. Clin Nephrol 50 6 (1998) 337-341
24. Aso Y., Inukai T., and Takemura Y. Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: possible application as a marker for vascular endothelial injury. Metabolism 47 3 (1998) 362-365
25. van Dam M.J., de Groot E., Clee S.M., Hovingh K., Roelants R., Brooks-Wilson A., et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 359 9300 (2002) 37-42
26. Lempiainen P., Mykkanen L., Pyorala K., Laakso M., and Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100 2 (1999) 123-128
27. Anand S.S., Yi Q., Gerstein H., Lonn E., Jacobs R., Vuksan V., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 4 (2003) 420-425
28. Sakkinen P.A., Wahl P., Cushman M., Lewis M.R., and Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152 10 (2000) 897-907
29. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Bonadonna R.C., et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 26 4 (2003) 1251-1257
30. Hulthe J., Bokemark L., Wikstrand J., and Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20 9 (2000) 2140-2147
31. Olijhoek J.K., van Der Graaf Y., Banga J.D., Algra A., Rabelink T.J., Visseren F.L., et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 25 4 (2004) 342-348
32. Hsia J., Bittner V., Tripputi M., and Howard B.V. Metabolic syndrome and coronary angiographic disease progression: the women's angiographic vitamin & estrogen trial. Am Heart J 146 3 (2003) 439-445
33. Meigs J.B., Mittleman M.A., Nathan D.M., Tofler G.H., Singer D.E., Murphy-Sheehy P.M., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham offspring study. JAMA 283 2 (2000) 221-228
34. Juhan-Vague I., Alessi M.C., Mavri A., and Morange P.E. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1 7 (2003) 1575-1579
35. Sobel B.E., Woodcock-Mitchell J., Schneider D.J., Holt R.E., Marutsuka K., Gold H., et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97 22 (1998) 2213-2221
36. Beishuizen E.D., van de Ree M.A., Jukema J.W., Tamsma J.T., van der Vijver J.C., Meinders A.E., et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 27 12 (2004) 2887-2892
37. Evans M., Anderson R.A., Graham J., Ellis G.R., Morris K., Davies S., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101 15 (2000) 1773-1779
38. Beishuizen E.D., Tamsma J.T., Jukema J.W., van de Ree M.A., van der Vijver J.C., Meinders A.E., et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 28 7 (2005) 1668-1674
39. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., Lam K.S., et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87 2 (2002) 563-568